References
- Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis. 2019;14(1):263–292.
- CDC.gov [Internet]. Data & statistics on sickle cell disease. Washington (DC): Centers for Disease Control and Prevention; [2022 May 2; cited 2023 Mar 3]. Available from: https://www.cdc.gov/ncbddd/sicklecell/data.html
- Shah N, Bhor M, Xie L, et al. Sickle cell disease complications: prevalence and resource utilization. PLOS One. 2019;14(7):e0214355.
- Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17–25.
- Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 2005;84(6):363–376.
- Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94–101.
- Yusuf HR, Atrash HK, Grosse SD, et al. Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999–2007. Am J Prev Med. 2010;38(4):S536–S541.
- Huo J, Xiao H, Garg M, et al. The economic burden of sickle cell disease in the United States. Value Health. 2018;21:S108.
- Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323–327.
- FDA.gov [Internet]. The FDA encourages new treatments for sickle cell disease; [2018 Jun 18; cited 2022 Jul 11]. Available from: https://www.fda.gov/consumers/consumer-updates/fda-encourages-new-treatments-sickle-cell-disease.
- Adakveo®. Package Insert. 2019. [cited 2023 Mar 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
- Shah N, Bhor M, Xie L, et al. Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: a retrospective claims study. J Health Econ Outcomes Res. 2020;7(1):52–68.
- Lobo C, Moura P, Fidlarczyk D, et al. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country. BMC Health Serv Res. 2022;22(1):42.
- Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
- Medicaid.gov. 2019. [cited 2023 Mar 3]. Medicaid and CHIP enrollment data highlights. Available from: https://www.medicaid.gov/medicaid/program-information/medicaid-and-chip-enrollment-data/report-highlights/index.html.
- Elsharawy MA, Moghazy KM, Shawarby MA. Atherosclerosis in sickle cell disease – a review. Int J Angiol. 2009;18(02):62–66.
- Usmani A, Machado RF. Vascular complications of sickle cell disease. Clin Hemorheol Microcirc. 2018;68(2–3):205–221.